320 related articles for article (PubMed ID: 19238210)
1. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Petty RD; Dahle-Smith A; Stevenson DAJ; Osborne A; Massie D; Clark C; Murray GI; Dutton SJ; Roberts C; Chong IY; Mansoor W; Thompson J; Harrison M; Chatterjee A; Falk SJ; Elyan S; Garcia-Alonso A; Fyfe DW; Wadsley J; Chau I; Ferry DR; Miedzybrodzka Z
J Clin Oncol; 2017 Jul; 35(20):2279-2287. PubMed ID: 28537764
[TBL] [Abstract][Full Text] [Related]
4. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
Yokoyama T; Kondo M; Goto Y; Fukui T; Yoshioka H; Yokoi K; Osada H; Imaizumi K; Hasegawa Y; Shimokata K; Sekido Y
Cancer Sci; 2006 Aug; 97(8):753-9. PubMed ID: 16863509
[TBL] [Abstract][Full Text] [Related]
5. Second-Line Therapy for Advanced NSCLC.
Weiss JM; Stinchcombe TE
Oncologist; 2013; 18(8):947-53. PubMed ID: 23918070
[TBL] [Abstract][Full Text] [Related]
6. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Wang M; Kern AM; Hülskötter M; Greninger P; Singh A; Pan Y; Chowdhury D; Krause M; Baumann M; Benes CH; Efstathiou JA; Settleman J; Willers H
Cancer Res; 2014 May; 74(10):2825-34. PubMed ID: 24648348
[TBL] [Abstract][Full Text] [Related]
7. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.
Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL; McLellan MD; Zakowski MF; Lash AE; Kasai Y; Broderick S; Sarkaria IS; Pham D; Singh B; Miner TL; Fewell GA; Fulton LL; Mardis ER; Wilson RK; Kris MG; Rusch VW; Varmus H; Pao W
PLoS One; 2007 May; 2(5):e426. PubMed ID: 17487277
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer.
Kurup S; Gesinski D; Assaad K; Reynolds A
Bioorg Med Chem Lett; 2024 Mar; 100():129612. PubMed ID: 38199330
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Chen Y; Huang R; Ding J; Ji D; Song B; Yuan L; Chang H; Chen G
Sci Rep; 2015 Apr; 5():9925. PubMed ID: 25894462
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
Ahmadi A; Mohammadnejadi E; Razzaghi-Asl N
Comput Biol Med; 2023 Sep; 163():107204. PubMed ID: 37421739
[TBL] [Abstract][Full Text] [Related]
12. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.
Cai X; Sheng J; Tang C; Nandakumar V; Ye H; Ji H; Tang H; Qin Y; Guan H; Lou F; Zhang D; Sun H; Dong H; Zhang G; Liu Z; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Jones L; Huang XF; Chen SY; Wu T; Lin H
PLoS One; 2014; 9(4):e95228. PubMed ID: 24760004
[TBL] [Abstract][Full Text] [Related]
13. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.
Kalinowski FC; Giles KM; Candy PA; Ali A; Ganda C; Epis MR; Webster RJ; Leedman PJ
PLoS One; 2012; 7(10):e47067. PubMed ID: 23115635
[TBL] [Abstract][Full Text] [Related]
14. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
[TBL] [Abstract][Full Text] [Related]
16. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Herrera-Abreu MT; Pearson A; Campbell J; Shnyder SD; Knowles MA; Ashworth A; Turner NC
Cancer Discov; 2013 Sep; 3(9):1058-71. PubMed ID: 23744832
[TBL] [Abstract][Full Text] [Related]
17. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
[TBL] [Abstract][Full Text] [Related]
18. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Ruan Z; Katiyar S; Kannan N
Biochemistry; 2017 Jan; 56(1):22-32. PubMed ID: 27936599
[TBL] [Abstract][Full Text] [Related]
19. Variant Analysis of miRNA Regulatory Genes in 35 Sporadic Lung Carcinoma Tumors.
Bağcı Ö; Özdemir EM; Şanlıtürk B
Dokl Biochem Biophys; 2023 Dec; 513(Suppl 1):S1-S7. PubMed ID: 38472669
[TBL] [Abstract][Full Text] [Related]
20. In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.
Wanika L; Evans ND; Johnson M; Tomkinson H; Chappell MJ
Clin Transl Sci; 2024 Mar; 17(3):e13714. PubMed ID: 38477045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
